このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Shineco 過去の業績

過去基準チェック /06

Shinecoの収益は年間平均-14.6%の割合で減少していますが、 Personal Products業界の収益は年間増加しています。収益は年間14.8% 63.1%割合で減少しています。

主要情報

-14.6%

収益成長率

13.9%

EPS成長率

Personal Products 業界の成長	20.9%
収益成長率	-63.1%
株主資本利益率	-35.9%
ネット・マージン	-255.1%
前回の決算情報	31 Mar 2024

Recent updates

Shineco CEO steps down, new CEO appointed

May 07

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

May 04

収支内訳

Shineco の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:SISI 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費
31 Mar 24	6	-14	15
31 Dec 23	5	-14	14
30 Sep 23	2	-12	10
30 Jun 23	1	-10	9
31 Mar 23	-2	2	0
31 Dec 22	-1	2	-1
30 Sep 22	-1	2	-1
30 Jun 22	0	-8	6
31 Mar 22	3	-28	23
31 Dec 21	3	-28	23
30 Sep 21	3	-31	24
30 Jun 21	3	-21	17
31 Mar 21	-6	-11	5
31 Dec 20	-3	-13	7
30 Sep 20	4	-7	6
30 Jun 20	10	-7	8
31 Mar 20	26	-5	11
31 Dec 19	30	-2	11
30 Sep 19	31	-2	11
30 Jun 19	31	1	9
31 Mar 19	32	-2	9
31 Dec 18	38	4	6
30 Sep 18	44	7	6
30 Jun 18	44	8	6
31 Mar 18	43	12	4
31 Dec 17	38	9	4
30 Sep 17	35	8	4
30 Jun 17	34	8	3
31 Mar 17	34	8	4
31 Dec 16	33	7	4
30 Sep 16	34	8	4
30 Jun 16	35	8	4
31 Mar 16	35	8	4
31 Dec 15	34	8	4
30 Sep 15	33	7	4
30 Jun 15	33	7	4
31 Mar 15	32	10	3
31 Dec 14	32	8	3
30 Sep 14	30	7	3
30 Jun 14	31	8	2
31 Mar 14	34	7	3
30 Jun 13	35	6	2

質の高い収益: SISIは現在利益が出ていません。

利益率の向上: SISIは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: SISIは利益が出ておらず、過去 5 年間で損失は年間14.6%の割合で増加しています。

成長の加速: SISIの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: SISIは利益が出ていないため、過去 1 年間の収益成長をPersonal Products業界 ( 6.9% ) と比較することは困難です。

株主資本利益率

高いROE: SISIは現在利益が出ていないため、自己資本利益率 ( -35.89% ) はマイナスです。

Shineco 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Full year 2023 earnings released: US$0.54 loss per share (vs US$2.60 loss in FY 2022)

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.30 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.32 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.17 loss per share (vs US$1.34 loss in 1Q 2022)

Full year 2022 earnings released: US$2.60 loss per share (vs US$4.73 loss in FY 2021)

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Recent updates

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shineco Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Requirement Under Nasdaq Listing Rule 5550(a)(2)

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

New major risk - Financial position

Shineco, Inc., Annual General Meeting, Feb 01, 2024

Shineco, Inc. Announces the Appointment of Two New Executive Officers

New major risk - Share price stability

New major risk - Financial position

Full year 2023 earnings released: US$0.54 loss per share (vs US$2.60 loss in FY 2022)

Shineco Not Regains Compliance with the Nasdaq's Minimum Bid Price Requirement

Shineco, Inc.'S Subsidiary, Changzhou Biowin Pharmaceutical Co., Ltd., Receives Marketing Approval from China's Regulatory Body for Its Cardiac 5 Minute Test

New major risk - Market cap size

Shineco, Inc., Annual General Meeting, Jun 28, 2023

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.30 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.32 loss in 2Q 2022)

Shineco, Inc. (NasdaqCM:SISI) signed a letter of intent to acquire 80% stake in Dream Partner Limited for $40 million.

First quarter 2023 earnings released: US$0.17 loss per share (vs US$1.34 loss in 1Q 2022)

High number of new and inexperienced directors

Shineco Receives Deficiency Letter from Nasdaq

Full year 2022 earnings released: US$2.60 loss per share (vs US$4.73 loss in FY 2021)

Shineco, Inc. Appoints Aamir Ali Quraishi as Independent Director

Shineco, Inc. Resigns Yanzeng as Member of the Board of Directors

High number of new and inexperienced directors

Shineco, Inc. Announces Management Changes

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Shineco, Inc. Appoints Qiyin Sun as Chief Medical Consultant

High number of new directors

Shineco, Inc. (NasdaqCM:SISI) entered into an agreement to acquire 51% stake in Xiang Peng You Kang (Beijing) Technology Co., Ltd.

Independent Director Harry Edelson has left the company

High number of new directors

Third quarter 2021 earnings released: US$2.36 loss per share (vs US$1.26 loss in 3Q 2020)

Shineco CEO steps down, new CEO appointed

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding terms of proposal to acquire a 51% stake in Mayah Biological Holdings Limited.

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

Shineco, Inc. announced delayed 10-Q filing

New 90-day high: US$4.15

New 90-day high: US$3.82

New 90-day high: US$3.31

First quarter 2021 earnings released: US$0.35 loss per share

Full year earnings released - US$2.25 loss per share

New 90-day low - US$2.71

Shineco, Inc. Announces Management Changes

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding Letter of Intent to acquire 73.7% stake in Changzhou Biowin Pharmaceutical Co., Ltd from Beijing Kanghuayuan Technology Development Co., Ltd and Changzhou Kelinbo Venture Capital Partnership (limited partnership) for $25 million.

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06